In summary, although deal volume is down, there are fewer but larger deal sizes. Life sciences companies that can demonstrate ...

Meanwhile at SpinCo, a new spinoff of Galapagos, Henry Gosebruch was appointed CEO. Gosebruch was previously president and ...

As has been widely reported on, immunisation rates, including for flu and RSV, have been falling – at a troubling rate – and ...

Roche's Itovebi was the first PI3K inhibitor to get approved as a first-line treatment for breast cancer last year – and new ...

Final draft guidance from NICE has backed NHS use of Filspari (sparsentan) for primary immunoglobulin A nephropathy (IgAN), ...

In particular, the organisation is unhappy with Kennedy's repeated assertions that Alzheimer's research has been dedicated to ...

While not the first biologic to break into the COPD sector – Sanofi and Regeneron took that crown with the approval of their ...